National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:Y 90 AHN-12



Previous:Xyotax, Y-90 OctreoTher, YM598, yoshi-864, yttrium Y 90 anti-CD19 monoclonal antibody BU12
Next:yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, yttrium Y 90 daclizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, yttrium Y 90 DOTA monoclonal antibody HuAFP31

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov